NCT01767129View on ClinicalTrials.gov

Safety and Efficacy of AVP-923 in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

October 16, 2013

Primary Completion Date

February 5, 2015

Study Completion Date

February 5, 2015

Conditions
DyskinesiaParkinson's Disease
Interventions
DRUG

AVP-923-45

One capsule twice daily for 14 days

DRUG

Placebo

One capsule twice daily for 14 days

Trial Locations (3)

60612

Chicago

97239

Portland

M5T 2S8

Toronto

Sponsors
All Listed Sponsors
collaborator

Michael J. Fox Foundation for Parkinson's Research

OTHER

lead

Avanir Pharmaceuticals

INDUSTRY

NCT01767129 - Safety and Efficacy of AVP-923 in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease Patients | Biotech Hunter | Biotech Hunter